By: Punit Sahu

Ranbaxy
 Content’s
 Introduction
 History
 Mission and Vision
 Values
 Life @ Ranbaxy
 Ranbaxy –Daiichi Sankyo Partnership
 Corporate Social Responsibility
 R & D
 Board of Director’s
 Ranbaxy's Top Products
 Global manufacturing strength
 Global sales
 Market shares & market review
 Contact us!!!!!
 Introduction

Ranbaxy is the India's largest pharmaceutical company,
Incorporated in1961. Headquarters Located in Gurgaon,
Haryana,india.
 The company went public in 1973, and Japanese

company Daiichi Sankyo gained majority control in 2008.

.
 Worldwide Presence
 Ground presence in 46 countries, products sold in over 125
countries.
 Manufacturing locations in 7 countries.

 Atul Sobti is currently Ranbaxy CEO and M.D., having taken

over from Malvinder Singh in May 2009.
 Cont…
History of Ranbaxy
 Ranbaxy was started by Ranbir Singh and Gurbax Singh in
1937 as a distributor for a Japanese company Shionogi.

 The name Ranbaxy is a portmanteau word from the names of its first owners
Ranbir and Gurbax.

 Bhai Mohan Singh bought the company in 1952 and after that Mohan
Singh and Shivinder Mohan Singh sold the company to the Japanese company
Daiichi Sankyo in June 2008.
CORPORATE OFFICE
 Mission

To become a Research-based International

Pharmaceutical Company

Vision –2012

Achieve significant business

in proprietary prescription products by 2012
with a strong presence in developed markets

Aspirations –2012

•Aspire to be a $5 Billion Company

•Become a Top 5 Global Generics Player
•Significant Income from Proprietary Products
 value
•Achieving customer satisfaction is fundamental of business

•Provide products and services of the highest quality

•Practice dignity and equity in relationship and provide

opportunities for our people to realise their full potential

•Ensure profitable growth and enhance wealth of the

shareholders

•Foster mutually beneficial relations with all our business

partners

•Manage our operations with high concern for safety and

environment

•Be a responsible corporate citizen

 Life @Ranbaxy
A career at Ranbaxy means an opportunity for ample learning & growth.
It offers avenues to work across the globe along side the finest minds. The
Company offers a challenging assignment, a world class working
environment, professional management, competitive salaries, stock options
along with exceptional rewards.
If you have an appetite for challenges, we have an exciting career for you

Opportunities
The global spread of Ranbaxy and the blazing growth in business
provides ample opportunities for our employees to build careers in
various fields.
Our managers will generally have the opportunity to live and
work in different countries; such international experience will
help them better understand our complex business and grow
both personally and professionally.
 Ranbaxy –Daiichi Sankyo Partnership

•A path breaking confluence that redefines the global pharma paradigm..

•Provides solutions to key need-gaps for each organization.

•Strategic combination creates an Innovator and Generic Pharmaceutical

Powerhouse.

•Combined entity is ranked among the Top 20 global pharmaceutical companies

•Ranbaxy enters into a new orbit to chart a higher trajectory.

•Complementary strengths ranging from excellence in NDDR to extensive reach

across globalmarkets.

•Financially & strategically beneficial for all stakeholders.

 Corporate Social Responsibility
CREATING VALUE…
VALUING LIFE…
• An essential component of Ranbaxy's CSR is
to care for the community.

• Based on the theme „Health For All‟ setup

Ranbaxy Rural Development Trust‟ in 1978;
later re-christened as „Ranbaxy Community
Health Care Society‟ in 1994.

• Operates in the states of Punjab, Haryana,

H.P.,MP.and Delhi /Gurgaon to provide

integrated health care to about 2 lakh people

staying in 100 villages and urban slum areas…..
 Research & Development
R&D I R&D III
R&D II

State-of-the-art R&D facilities

R&D IV
based in India

Dr. Sudershan K. Arora (L)

President - R&D (Generics, NDDS &
Drug Development)
Dr. Pradip Kumar Bhatnagar (R)
Sr. Vice President, New Drug
Discovery Research
 Research & Development
•Dedicated Facilities for Innovative & Generics Research

•1400 R&D Personnel ( ~ 300 Doctorates)

•Highest R&D spender across industry

•8 -10 NCE molecules in pipeline

•NDDS based products (4 platform technologies)

•R&D collaborations

Alliance / Collaboration Out-licensing

in NDDR In NDDS

Alliance / Collaboration
Out-licensing in NDDR
In NDDS
 Chairman, CEO & M.D.

Malvinder Mohan Singh

Dr. Tsutomu Une Chairman Chairman, CEO & M. D.
 Board of Directors

Dr. Tsutomu Une Mr. Takashi Shoda

Chairman Non Executive & Mr. Atul Sobti Mr. Rajesh V.
Non Executive & Non Independent C E O & M D Shah
Non Independent Director Independent
Director Director

Dr. Anthony H. Wild Mr. Rajesh V. Shah Mr. Percy Shroff

Independent Director Independent Director Independent Director
Ranbaxy’s Top Products
Simvastatin
control hypercholesterolemia & to prevent
cardiovascular disease
AmoxiClav Potassium
Used to treat a broad-spectrum of bacterial
infections,
Isotretinoin
for the treatment of brain cancer,
pancreatic cancer
Ciprofloxacin
It kills bacteria by interfering
Omeprazole
used in the treatment of dyspepsia
 Developed Markets Presence

•Largest generic market worldwide

•Significant patent expiries through 2011
USA

•Germany, UK -mature markets

•France, Spain, Italy, Romania -emerging markets
EU •Ranbaxy has presence in 23 of the 27 EU countries

•Mature generic market

•Ranbaxy is the fastest growing generics company in
CANADA Canada
•Emerging generic market, < 5% generic
penetration
JAPAN •1stIndian pharma company
 Global Manufacturing Strengths
• cGMP compliant world-class API & Dosage Forms
manufacturing facilities across the globe
• 7 manufacturing locations worldwide
• API facilities -increasing vertical integration
• Creating capacities for specialty products
• New facilities added in cost advantageous geographies

USA Ireland Romania Nigeria

India South Africa Malaysia

 Global Sales Split

CIS Asia

North
America

RoW

API
Europe

Global Sales (2009): US $ 1519Mn

 Evolution of Market Mix

Others
7%
Emerging
54%

Developed
39%

FY 2005 FY 2009
•Improving balance in market mix
•Growth well spread across geographies
•Positioned to leverage various market
opportunities.
 Market Share of Ranbaxy
 Global Markets Mix 2008
54% & Emerging
The Company is currently ranked 2nd in the Indian
pharmaceutical market with 4.98% market share (IMS, Oct-
Dec’09).

 Global sales in 2009 were USD 1,519 Mn (Rs. 73,441 Mn),

De-growth of 9% over previous year. In Rupee terms, sales
grew moderately by 1%. Sales during the Quarter recorded
growth of 25% at USD 482 Mn (Rs. 22,699 Mn). Emerging
markets accounted for 54% of sales during the year, while
developed markets contributed 39%.
REVENUE AND PROFIT AFTER TAX
Key competitors
GlaxoSmithKline

RPG Enterprises

East India Pharmaceutical

Dr. Reddy's Laboratories

Cipla Ltd

Dabur India Ltd

 Forecasts
 For 2010, the company forecast a 48% growth in net profit to Rs460
crore from Rs311 crore in 2009, and a 6% rise in sales to around
Rs7,800 crore.
 “Ranbaxy’s overall numbers appear fine but their guidance for
2010 is disappointing,” said a Mumbai-based analyst with a foreign
brokerage, asking not to be named as he’s not authorized to speak
to the media.
 “If they will have sales revenue from exclusive launches of generic
versions of Valtrex and Flomax as well as Nexium supplies to
AstraZeneca Plc in 2010, then why will growth in the year be only
6% on sales?”
 The December quarter’s profit was backed by revenue from the
exclusive launch of two major drugs in the US—generic versions of
anti-herpes drug Valtrex and epilepsy medicine Trileptal—and a
hold on costs in various markets, including in Europe
 Ranbaxy Laboratories Limited
Corporate Office
Plot 90, Sector 32,
Gurgaon -122001 (Haryana), INDIA
Ph: 91- 124- 4135000
Fax: 91-124-4135001
Web site:- www.ranbaxy.com